SGRX revenueFY2025$39.5K
- FY YoY
- -98.6%
- 5Y CAGR
- -72.3%
SGRX revenue was $39.5K for fiscal 2025 (ended Jun 30, 2025), down 98.6% from fiscal 2024. Compound annual growth was -72.3% over 5 years. It rose in 2 of the last 8 fiscal years.
SANGRIX INC. (SGRX) financials
For fiscal 2026 (ended Jun 30, 2026), SANGRIX INC. reported -$23.93M of net income.
- Net income, FY2026
- -$23.93M
- EPS, diluted, FY2026
- -$70.43
- Cash
- $1.57M
- Market cap
- $1.8M
FY2017FY2025
FY2017FY2026
FY2017FY2023
SGRX revenue and earnings growth
SGRX net incomeFY2026-$23.93M
SGRX net income was -$23.93M for fiscal 2026 (ended Jun 30, 2026), compared with -$6.53M in fiscal 2025.
SGRX EPSFY2026-$70.43
SGRX diluted EPS was -$70.43 for fiscal 2026 (ended Jun 30, 2026).
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $39.5K | $2.89M | $6.26M | $6.26M | $80.50M | $24.25M | $99.08M | $101.10M | $63.28M |
| Cost of revenue | - | - | $3.83M | $10.83M | $10.83M | $77.50M | $22.22M | $90.43M | $91.45M | $58.21M |
| Gross profit | - | $39.5K | -$945.2K | -$4.57M | -$4.57M | $3.00M | $2.03M | $8.65M | $9.65M | $5.07M |
| Selling, general and admin | $2.75M | $3.08M | $3.82M | $2.91M | $2.91M | $1.59M | $2.51M | $511.2K | $981.3K | $515.6K |
| Operating income | -$14.28M | -$2.99M | -$14.84M | -$28.30M | -$28.30M | -$3.47M | -$3.44M | -$511.2K | $7.04M | $3.52M |
| Interest expense | - | $665.2K | $595.7K | $227.4K | $227.4K | $156.0K | $123.2K | $730.8K | $1.28M | $667.7K |
| Pre-tax income | -$14.29M | -$4.37M | -$18.28M | -$28.22M | -$28.22M | -$3.64M | -$3.92M | -$510.4K | $4.48M | $3.33M |
| Income tax | - | - | - | - | - | -$1.00M | $223.2K | $213.6K | $714.4K | $875.7K |
| Net income | -$23.93M | -$6.53M | -$17.53M | -$28.22M | -$28.22M | -$45.61M | -$4.88M | $4.36M | $3.77M | $2.45M |
| EPS, basic | -$70.43 | -$84.84 | -$1003.41 | -$2583.00 | -$2583.00 | -$987.00 | -$1620.00 | -$270.00 | $1710.00 | $1080.00 |
| EPS, diluted | -$70.43 | -$84.84 | -$1003.41 | -$2583.00 | -$2583.00 | -$987.00 | -$1620.00 | -$180.00 | $1710.00 | $1080.00 |
| Diluted shares | 339,699 | 77,016 | 17,472 | 10,930.163 | 10,930.163 | 3,688.263 | 2,490.836 | 2,327.217 | 2,231.461 | 2,222.222 |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.57M | $55.6K | $1.41M | $16.3K | $17.8K | $1.9K | $163.6K | $2.68M | $319.1K | $21.5K |
| Receivables | - | - | $117.0K | $0 | $0 | $11.14M | $9.83M | $39.52M | $24.36M | - |
| Inventory | - | - | - | - | - | $229.4K | $0 | $112.6K | $2.7K | - |
| Current assets | $10.17M | $3.54M | $6.68M | $3.57M | $23.93M | $32.52M | $50.28M | $45.70M | $29.04M | - |
| Goodwill | - | - | - | - | - | $0 | $5.19M | $0 | - | - |
| Total assets | $21.16M | $3.54M | $6.68M | $13.34M | $34.95M | $40.88M | $63.35M | $51.35M | $33.73M | - |
| Current liabilities | $1.46M | $372.1K | $2.49M | $2.59M | $300.0K | $38.70M | $32.74M | $22.83M | $16.91M | - |
| Short-term debt | - | - | - | - | - | $9.89M | $7.56M | $0 | $4.91M | - |
| Total liabilities | $12.08M | $372.1K | $5.78M | $3.07M | $300.0K | $42.50M | $36.52M | $26.83M | $17.90M | - |
| Shareholders' equity | $5.62M | $3.90M | $909.6K | $10.26M | $34.65M | -$1.62M | $26.83M | $24.53M | $14.03M | $10.13M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.92M | -$2.29M | -$7.93M | -$6.76M | -$14.24M | -$10.39M | -$5.91M | -$5.27M | -$3.60M | -$2.51M |
| Capital expenditures | - | - | - | $115.0K | $8.30M | - | $700.4K | $20.6K | $89.4K | $11.7K |
| Free cash flow | - | - | - | -$6.88M | -$22.54M | - | -$6.61M | -$5.29M | -$3.68M | -$2.53M |
| Investing cash flow | -$200.0K | $1.55M | $1.02M | $4.27M | -$11.31M | $0 | $159.1K | $1.19M | -$89.4K | -$11.7K |
| Financing cash flow | $4.64M | -$608.7K | $8.30M | $2.49M | $25.94M | $8.50M | $4.08M | $6.65M | $3.99M | $2.50M |
| Stock-based compensation | - | - | $73.2K | $67.3K | $1.62M | $1.89M | $930.2K | $0 | $0 | - |
| Depreciation and amortization | - | - | - | - | - | - | - | $689.5K | $542.2K | $531.6K |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -98.6% | -53.9% | 0.0% | -92.2% | 232.0% | -75.5% | -2.0% | 59.8% | - |
| Net income growth, YoY | - | - | - | - | - | - | - | 15.8% | 53.5% | - |
| EPS growth, YoY | - | - | - | - | - | - | - | - | 58.3% | - |
| Gross margin | - | 100.0% | -32.7% | -72.9% | -72.9% | 3.7% | 8.4% | 8.7% | 9.5% | 8.0% |
| Operating margin | - | -7574.9% | -513.6% | -452.1% | -452.1% | -4.3% | -14.2% | -0.5% | 7.0% | 5.6% |
| Net margin | - | -16543.8% | -607.0% | -450.7% | -450.7% | -56.7% | -20.1% | 4.4% | 3.7% | 3.9% |
| Free cash flow margin | - | - | - | -109.8% | -360.0% | - | -27.3% | -5.3% | -3.6% | -4.0% |
| Return on equity | -425.7% | -167.5% | -1927.4% | -275.0% | -81.4% | - | -18.2% | 17.8% | 26.9% | 24.2% |
| Return on assets | -113.1% | -184.8% | -262.3% | -211.6% | -80.7% | -111.6% | -7.7% | 8.5% | 11.2% | - |
| Current ratio | 6.98 | 9.50 | 2.68 | 1.38 | 79.77 | 0.84 | 1.54 | 2.00 | 1.72 | - |
Source: XBRL data SANGRIX INC. files with the SEC, latest filing dated Sep 18, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Oct 31, 2023; 1-for-300, first reported Sep 18, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
SGRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SGRX | - | - | -$23.93M | - | $1.8M |
| AXP | $77.59B | +10.2% | $12.26B | 15.8% | $217.47B |
| SPGI | $17.21B | +18.2% | $4.99B | 29.0% | $136.57B |
| MCO | $8.18B | +9.0% | $2.88B | 35.3% | $88.11B |
| NU | $15.77B | +37.0% | $2.87B | 18.2% | $60.02B |
| RKT | $11.46B | +90.4% | $1.30B | 11.4% | $43.11B |
| COIN | $5.63B | -26.6% | -$701.62M | -12.5% | $36.03B |
| AFRM | $4.59B | +32.7% | $2.01B | 43.9% | $23.06B |
| SYF | $19.31B | +2.6% | $3.33B | 17.3% | $22.80B |
SGRX FAQ
6 questionsIs SGRX profitable?
No. SANGRIX INC. reported a net loss of $23.93M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does SGRX have?
SANGRIX INC. reported $1.57M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is SGRX revenue growing?
SANGRIX INC.'s revenue changed -98.6% in fiscal 2025, to $39.5K. Its compound annual growth rate was -72.3% over 5 years.What is SGRX earnings per share?
Diluted earnings per share were -$70.43 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did SGRX last report financial results?
The latest statements here come from SANGRIX INC.'s 20-F filed on Sep 18, 2026, covering the period ended Jun 30, 2026.Where does this SGRX financial data come from?
Quantisnow builds these statements from the structured XBRL data SANGRIX INC. files with the SEC. It is provided for information only and is not investment advice.